Ani Pharmaceuticals (ANIP) Equity Income (2024 - 2026)

Ani Pharmaceuticals has disclosed Equity Income across 3 years of filings, most recently posting $5.8 million for Q1 2026.

• Equity Income for Q1 2026 came in at $5.8 million, up 744.44% year-over-year; the trailing twelve-month figure through Mar 2026 was $9.5 million (up 324.32% YoY), and the FY2025 annual result was $2.8 million, down 55.17% from the prior year.
• Equity Income came in at $5.8 million for Q1 2026 at Ani Pharmaceuticals, up from $273000.0 in the prior quarter.
• In the past five years, Equity Income ranged from a high of $9.7 million in Q1 2024 to a low of -$2.7 million in Q2 2024.
• The 3-year median for Equity Income is $332000.0 (2025), against an average of $1.7 million.
• Across the five-year window, Equity Income plunged 109.32% in 2025 and soared 744.44% in 2026, its largest moves.
• Ani Pharmaceuticals' Equity Income stood at -$2.0 million in 2024, then jumped by 113.66% to $273000.0 in 2025, then surged by 2024.54% to $5.8 million in 2026.
• The last three Equity Income figures came in at $5.8 million (Q1 2026), $273000.0 (Q4 2025), and $3.1 million (Q3 2025), per Business Quant data.